The company showcased new PET and SPECT technologies, imaging software, and radiopharmaceuticals aimed at supporting theranostics, quantitative imaging, and nuclear medicine workflows.

GE HealthCare is highlighting new imaging technologies, software, and radiopharmaceuticals at the 2026 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), reflecting ongoing growth in theranostics, molecular imaging, and precision medicine.

According to the company, increasing adoption of theranostics, growing demand for radiopharmaceuticals, and expanded use of precision diagnostics are driving healthcare organizations to scale nuclear medicine services while improving workflow efficiency and diagnostic confidence.

“Nuclear medicine is moving from early innovation to large-scale clinical implementation,” says Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare, in a release.

Clinical Applications

GE HealthCare highlighted several areas where it says nuclear medicine technologies are being integrated into clinical workflows.

In cardiology, the company pointed to Flyrcado (flurpiridaz F 18 injection), a PET imaging agent approved for myocardial perfusion imaging in patients with known or suspected coronary artery disease.

In neurology, GE HealthCare highlighted Vizamyl (flutemetamol F 18 injection) for amyloid PET imaging and MIMneuro software, which are used to support evaluation of Alzheimer’s disease and other causes of cognitive decline.

For oncology and theranostics applications, the company emphasized technologies including the StarGuide SPECT/CT system, Intelligent Radiation Therapy (iRT), and its MIM software portfolio, which are designed to support imaging, treatment planning, and response assessment.

“This is an exciting moment for nuclear medicine because we are moving beyond simply detecting disease to truly understanding its biology and behavior,” says Munir Ghesani, MD, chief medical officer at United Theranostics and system chief of nuclear medicine at Mount Sinai Health System, in a release.

Imaging and Software Updates

MIM LesionID Pro is an FDA-cleared software application that automates whole-body tumor burden analysis. Photo credit: GE HealthCare

Among the technologies showcased at SNMMI 2026 are:

  • MIM KineticID, a 510(k)-pending software platform for dynamic PET imaging and kinetic modeling.
  • MIM LesionID Pro, an FDA-cleared software application that automates whole-body tumor burden analysis.
  • Omni Legend, a PET/CT platform that incorporates deep learning image processing.
  • StarGuide, a digital SPECT/CT system featuring cadmium zinc telluride (CZT) detector technology.
  • MINItrace Magni, a compact cyclotron platform in development for on-site production of PET tracers and radiometals, including Gallium-68.

Radiopharmaceutical Portfolio

GE HealthCare also highlighted several radiopharmaceutical products used across nuclear medicine applications, including:

  • Flyrcado for cardiac PET imaging.
  • DaTscan for evaluation of patients with suspected Parkinsonian syndromes and dementia with Lewy bodies.
  • Cerianna for imaging estrogen receptor-positive lesions in recurrent or metastatic breast cancer.
  • Vizamyl for amyloid PET imaging in patients with cognitive impairment.

Focus on Quantitative Imaging

The company says quantitative imaging and advanced analytics are expected to play a growing role in theranostics and neurodegenerative disease management, where standardized image interpretation and longitudinal assessment may help support clinical decision-making across care settings.

GE HealthCare’s exhibits at SNMMI 2026 focus on imaging systems, software, and radiopharmaceutical technologies intended to support nuclear medicine workflows from diagnosis through treatment planning and monitoring.